TY - JOUR
T1 - An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons
AU - Saavedra-Lozano, Jesús
AU - McCoig, Cynthia
AU - Xu, Jinbo
AU - Cao, Yanying
AU - Keiser, Philip
AU - Ghetie, Victor
AU - Siliciano, Robert F.
AU - Siliciano, Janet D.
AU - Picker, Louis J.
AU - Ramilo, Octavio
AU - Vitetta, Ellen S.
N1 - Funding Information:
Received 20 July 2001; revised 4 October 2001; electronically published 8 January 2002. Presented in part: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 2000 (abstract 1165). The study was approved by the University of Texas Southwestern Medical Center at Dallas institutional review board. Informed consent was obtained from each subject before blood samples were obtained. Financial support: National Institutes of Health (AI-43222); State of Texas Higher Education Coordinating Board (010019-0100). a O.R. and E.S.V. codirected this study. Reprints or correspondence: Dr. Ellen S. Vitetta, University of Texas Southwestern Medical Center, Cancer Immunobiology Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8576 ([email protected]).
PY - 2002/2/1
Y1 - 2002/2/1
N2 - Highly active antiretroviral therapy has decreased the morbidity and mortality of human immunodeficiency virus (HIV) infection, but latently infected cells remain for prolonged periods. CD4+ CD45RO+ T cells are a major latent virus reservoir in HIV-infected persons. Replication-competent, latently HIV-infected T cells can be generated in vitro by infecting peripheral blood mononuclear cells with HIV and then eliminating the HIV-producing cells with an anti-CD25 immunotoxin (IT). The CD25- latently infected cells then can be eliminated with an anti-CD45RO IT. This study determined whether this IT also could kill latently infected CD4 T cells from HIV-infected persons with or without detectable plasma viremia. The results show that ex vivo treatment of cells from HIV-positive persons by anti-CD45RO IT reduces the frequency of both productively and latently infected cells. In contrast, CD4+ CD45A+ naive T cells and a proportion of CD4+ CD45ROlo memory T cells are spared.
AB - Highly active antiretroviral therapy has decreased the morbidity and mortality of human immunodeficiency virus (HIV) infection, but latently infected cells remain for prolonged periods. CD4+ CD45RO+ T cells are a major latent virus reservoir in HIV-infected persons. Replication-competent, latently HIV-infected T cells can be generated in vitro by infecting peripheral blood mononuclear cells with HIV and then eliminating the HIV-producing cells with an anti-CD25 immunotoxin (IT). The CD25- latently infected cells then can be eliminated with an anti-CD45RO IT. This study determined whether this IT also could kill latently infected CD4 T cells from HIV-infected persons with or without detectable plasma viremia. The results show that ex vivo treatment of cells from HIV-positive persons by anti-CD45RO IT reduces the frequency of both productively and latently infected cells. In contrast, CD4+ CD45A+ naive T cells and a proportion of CD4+ CD45ROlo memory T cells are spared.
UR - http://www.scopus.com/inward/record.url?scp=0036467792&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036467792&partnerID=8YFLogxK
U2 - 10.1086/338565
DO - 10.1086/338565
M3 - Article
C2 - 11807712
AN - SCOPUS:0036467792
SN - 0022-1899
VL - 185
SP - 306
EP - 314
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 3
ER -